Treating Cutaneous Leishmaniasis By Domestic Knowledge-Based Product in Pardis Technology Park

Behpad Teb Iranian Company, member of Pardis Technology Park has taken an effective step in the treatment of cutaneous leishmaniasis by producing Leish G1.

Cutaneous leishmaniasis is an infectious parasitic disease that exists in more than 100 countries.

Iran is no exception and many Iranian provinces such as Fars, Isfahan, Yazd, Sistan and Baluchestan, Ilam, Khuzestan, Khorasan, etc. are struggling with this disease.

CEO of Behpad Teb Iranian Company Nemati said that the topical cream has been produced in this company after years of research.

This product is completely indigenous and is produced from effective herbal ingredients after extensive clinical and laboratory studies, he added.

There is an injectable drug called glucantim in the world for the treatment of cutaneous leishmaniasis, which is used as an injection at the wound site, he noted.

In addition to being painful after use, this medicine in some cases causes serious complications in the patient's skin and body, he stated.

The Leish G1 effectiveness in small wounds is 100%, and in large wounds, it is similar to the foreign sample and around 85%, he noted.